Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Pharmacogenet Genomics. 2013 Sep;23(9):470–478. doi: 10.1097/FPC.0b013e328363c137

Fig. 1.

Fig. 1

(a) The results of tests for a trend in the association between angiotensin-converting enzyme (ACE) inhibitor-associated angioedema and each single-nucleotide polymorphism (SNP) measured in the GWAS in participants Nashville/Marshfield study (irrespective of ethnicity). The analysis was adjusted for age and sex. Rs2724635 and Rs500766, indicated in green, were associated with ACE inhibitor-associated angioedema in ONTARGET. (b) The results of tests for a trend in the association between ACE inhibitor-associated angioedema and each SNP measured in the GWAS in African Americans from the Nashville/Marshfield study. The analysis was adjusted for age and sex. Rs2724635, indicated in green, was associated with ACE inhibitor-associated angioedema in ONTARGET. (c) The results of tests for a trend in the association between ACE inhibitor-associated angioedema and each SNP measured in the GWAS in European Americans from the Nashville/Marshfield study. The analysis was adjusted for age and sex. Rs500766, indicated in green, was associated with ACE inhibitor-associated angioedema in ONTARGET.